AmerisourceBergen Corporation has acquired all of the outstanding stock of IgG of America, Inc., a specialty pharmacy and infusion services business specializing in the blood derivative IVIG, for approximately $35 million in cash.

The acquisition also includes a contingent payment of up to approximately $8.5 million based on IgG of America achieving specific earnings targets in calendar year 2008. The transaction is expected to be slightly accretive to the company's fiscal 2007 earnings.

"The addition of IgG of America supports AmerisourceBergen's strategy of building our specialty pharmaceuticals services to manufacturers," said R. David Yost, chief executive officer of AmerisourceBergen. "IgG is a leader in the IVIG area, and is an excellent addition to our services in the pharmaceutical supply channel."

Based in of Linthicum, Maryland, IgG of America had revenues of approximately $29 million over the last twelve months ended September 30, 2006. IgG will become part of the AmerisourceBergen Specialty Group.